Galapagos and MorphoSys have announced that they are ending the clinical development programme for their drug MOR106 in atopic dermatitis (also known as eczema).
The European Commission (EC) has extended the marketing authorisation for Sanofi and Regeneron's eczema drug Dupixent (dupilumab) to include adolescents, while new phase 3
Spain’s Almirall has taken an option granting rights to develop and market Dermira’s eczema drug lebrikizumab in Europe, in a bid to take on Sanofi/Regeneron's recently approved Dupixent.
Almirall has signed a new research collaboration with Chinese biotech HitGen, to find potential new oral therapies for moderate to severe atopic dermatitis – otherwise known as eczema.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
